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ABSTRACT 
Background: Autosomal dominant polycystic kidney disease (ADPKD) is an 
inherited disorder with genetic heterogeneity. Up to three loci are involved in this dis­
ease, PKDl on chromosome 16p13.3, PKD2 on 4q21, and a third locus of unknown 
location. 
Methods: Here we report the first molecular genetic study of ADPKD and the 
existence oflocus heterogeneity for ADPKD in the Iranian population by performing 
linkage analysis on 15 affected families. 
Results: Eleven families showed linkage to PKD 1 and two families showed link­
age to PKD2. In two families, PKD 1 markers are common in all affected members but 
PKD2 markers were not informative. 
Conclusion: The results of this study demonstrate significant locus heterogeneity 
in autosomal dominant PKD in Iran. Analysis of clinical data confirms a milder ADPKD 
phenotype for PKD2 families. Our results showed relatively high heterozygosity rates 
and PIC values for some markers, while the most informative markers were KG8 and 
16AC2.5 for PKD 1 gene and AFM224x6 for PKD2 gene. 
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INTRODUCTION 
Autosomal dominant polycystic kidney disease 
(ADPKD) is an hereditary systemic nephropathy (PKD 
[MIM 173900]), characterized by the development of 
cysts in the ductus organs (mainly the kidneys and the 
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liver), with gastrointestinal and cardiovascular abnor­
mali ties. 42 The kidney cysts gradually enlarge and their 
number grows, destroying in this way the functional pa­
renchyma (Fig. 1). As a consequence, the patients de­
velop chronic renal failure (CRF), which progresses to 
end-stage chronic renal failure (ESCRF), requiring sub­
stitutional therapy (hemodialysis or kidney transplanta­
tion). ADPKD patients may benefit if the diagnosis can 
be established before symptoms develop.58 
ADPKD is one of the most common genetic disorders. 
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Fig. 1. Comparison between enlarge polycystic kidney (left) and 
normal kidney (right). 
The gene frequency in the general population has been esti­
mated to be about 1 in 400-1,000 in the Western countries.42 
ADPKD is genetically heterogeneous and there are at least 
three possible loci involved in this disease.4 Mutations of the 
polycystic kidney disease 1 gene (PKDl [MIM 601313]) on 
chromosome 16p13.3 are the most common and account for 
about 85% of all cases of ADPKD. 5 The PKD 1 gene has been 
cloned, and the structure of its encoded complex protein, called 
polycystin, determined.7 The polycystic kidney disease 2 gene 
(PKD2 [MIM 173910]) is located on chromosome 4q21-23 .8 It 
is defective in most of the remaining ADPKD families.5•8 A 
small number of families are affected by one or more undeter­
mined loci (PKD3 [MIM 600666]), which do not map to the 
above loci. 
Direct screening for PKDl mutations in ADPKD is 
difficult due to the large gene size and extensive homol­
ogy of PKD I to other parts of the human genome.9 The 
PKD2 gene is more amenable because of its smaller size 
and absence of extensive homology to other parts of 
chromosome 4. However, no "hot-spot" mutation has 
been identified in the PKD 1 or PKD2 genes. 10 Genetic 
diagnosis through screening for defects in the PKD 1 
and PKD2 is technically possible but the cost and time 
involved are prohibitive and severely limit its clinical 
application. Alternative ways that identify the transmis­
sion of ADPKD are needed. In this communication, we 
report our finding of using DNA micro satellite marker 
analysis to determine the transmission of ADPKD in Ira­
nian families. 
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MATERIAL AND METHODS 
Normal population 
Genomic DNA of 150 unrelated healthy individuals 
from Iran were obtained. Based on those samples, we 
determined the allele frequencies, heterozygosity rate, 
and PIC values of the six microsatellite markers in our 
local population. 
ADPKD families and clinical evaluation 
Ethical approval for this study was given by the vari­
ous ethics committees of Iran. Informed consent was 
obtained from all individuals involved. Several families 
with the history of hereditary renal cysts were recruited 
and informed consent was obtained before our investi­
gation. The following criteria were used for diagnosis of 
ADPKD: (i) the presence of at least two renal cysts (uni­
lateral or bilateral) in an at-risk individual aged (30 years; 
(ii) the presence of at least two renal cysts in each kid­
ney in an at-risk individual aged 30-59 years; (iii) the 
presence of at least four renal cysts in each kidney in an 
at-risk individual aged >60 years. All living relatives in 
our four families were invited for this study. They had 
blood pressure (BP) measurements and WHO criteria for 
hypertension were used; patients were regarded as hy­
pertensive if the systolic blood pressure was 160 mmHg 
or higher or the diastolic blood pressure (Korotkoff 
phase V) was 95 mmHg or higher. Abdominal ultrasonog­
raphy and full biochemical studies was arranged, includ­
ing serum urea, creatinine, uric acid, urine microscopy, 
and a renal ultrasound. Urine studies for fractional ex­
traction of sodium (FENa), fractional excretion of uric 
acid (FEur), and protein/creatinine ratio were also per­
formed. Twenty-four hour urine collections for total pro­
tein excretion were performed in those with protein-urine 
on urine analysis studies. Creatinine clearance was cal­
culated according to sex, age, lean body mass (LBM), 
and serum creatinine based on the equation ( 1 40-
age )xLBM172xserum creatinine for males, or (140-age) x 
LBM/72xserum creatininex85% for females and was cor­
rected for a body surface area of 1.73 m2• Following their -
clinical assessments by nephrologists, the blood 
samples of each patient and first-degree relatives were 
collected for DNA extraction. A total of 4 affected kin­
dred were included in this study following informed con­
sent. A detailed family history was obtained from each 
subject. For some of the cases included here, since they 
died many years ago, there are no accurate clinical data 
and their children provided the information that they 
suffered from renal failure. 
Controls 
Controls were spouses of those affected in each fam-
R. Radpour, et al. 
ily as well as unaffected siblings of individuals with 
PKDl or PKD2 (normal renal imaging and linkage re­
sults showed that their genetic risk was less than 1 %). 
Affected individuals were matched with their partners 
whenever possible, irrespective of whether they were 
alive or dead. W hereas siblings had to have evidence 
that they were not affected to be eligible, spouses did 
not. Because in the absence of evidence of assortive 
mating for this disorder, affected individuals who could 
not be matched by partners were paired with individuals 
from the unaffected siblings selected on the basis of 
region, sex, and date of birth. For controls who had died, 
the age at death was recorded, and for the one control 
who had ESRD (cause unknown), the age at onset of 
this disease. Non-affected siblings who had died were 
included as controls only if there was proof that they 
did not have ADPKD. 
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Fig. 2. Genomic locations of the microsatellite markers relative to P KD 1 on chromosome 16 
and P KD 2 on chromosome 4.16.38 
Table I. Sequences and peR characteristics of PKD1 & PKD 2 specific primers. 
Name of Length Tm % Ge Size Gel running Annealing T 
Markers (mer) (Oe) Primer Sequence (bp) time (Oe) 
(hr. min) 
KG8 21 63 66 F: crCCCAGGGTGGAGGAAGGTG 116-130 3 .55 69 
21 65 7 1  R:GCAGGCACAGCCAGCfCCGAG 
..... � 16AC2.5 25 60 48 F: GCAGCCTCAGTTGTGTTTCC TAATC 154-170 4.15 63 Q., 
(D16S291) 25 61 52 R:AGTGCfGGGATTACAGGCATGAACC 
SM7 21 5 4  42 F:ACATATGTAGTCTTCTGCAGG 81 -107 3.20 57 
(DI6S283) 21 54 42 R:ACAAGAGTGAATCTCTGACAG 
AFM155xel1 1 8  50 44 F:ATTCAGTTTCAGCCCCAT 1 46-158 4.15 55 
(D4S1534) 18 57 61 R: ACCAGCCCAAGGTAGAGG 
"l YUNCA9 21 48 2 8  F:AGATGAGTATGTTATTATACC 154-169 4.45 55 � (D4S231) 1 8  5 3  50 R:TGCTAGAGTTCCCTAGTG Q., 
AFM 224x6 21 56 47 F:TTGAGTAGTTCCTGAAGCAGC 103 -125 3 .50 55 
(D4S423) 21 56 47 R: CAAAGTCCTCCATCTTGAGTG 
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Table IV. Comparison of ADPKD-l and ADPKD-2 in Iranian patients. 
At-risk subjects <30 All subjects <40 Subjects with cysts <40 Mean age of end-stage 
years old with renal cysts (%) years old with years old with renal renal disease (yr) 
hypertension (%) insufficiency (%) 
ADPKD-l 48 27 
ADPKD-2 11 8 
4-6). 
Family 1 203: 
In this family there has been a history of kidney dis­
ease with hypertension of fairly early onset. Multipoint 
analysis with polymorphic markers around PKDl and 
PKD2 genes gave evidence for linkage within the con-
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it is not carried by affected III: 7. Therefore, it is con­
cluded that ADPKD is linked to PKD 1 but not PKD2 in 
this family. Clinical evaluations confirmed this finding. 
Family 1 208: 
In this family haplotype for PKDl markers: 2,2,3 was 
common in all affected members (III:7, III: 10, III: 12, III: 14, 
IV: 1, IV:4 and IV:8) but for PKD2 markers since affected 
members have not a common haplotype in this family, 
the disease phenotype is most probably co-inherited 
with haplotype 2,2,3 and ADPKD is linked to PKDl lo­
cus (Fig. 5). 
Family 1 21 4: 
On the other hand, a different linkage pattern was 
observed in family 1214. This family showed statistically 
significant evidence of non-linkage to PKDI. The analy­
sis of chromosome 4 markers showed positive linkage to 
PKD2 10cus. In this family four ADPKD and three unaf­
fected members were studied. There was no common 
PKDl-linked haplotype shared by all the ADPKD af­
fected members (Fig. 6). There was common haplotype 
of PKD2 markers: 2,2,2 Carried by the ADPKD affected 
member 11:3, II:4, 11:6 and III:9. This haplotype was nei­
ther carried by unaffected persons (II: 1 and I1I:3). This 
finding indicating likely linkage to the PKD2 gene. 
Clinical findings and genotype/phenotype correlations 
A total of 135 subjects from IS Iranian ADPKD fami­
lies were studied for the purpose of this report. The total 
number of patients originating from linked to PKDl was 
68 and that of patients from PKD2 families was 25. To­
tally, 93 investigated subjects were affected (ADPKD 1 
or ADPKD2), 31 blood relatives were unaffected (at risk 
subjects), and 11 were spouses. In the PKDI families, 
all members 30 years of age with affected relatives and a 
PKDl associated haplotype, had detectable cysts (Table 
III). No member entered ESRD below the age of 40. Sev­
enteen subjects developed chronic renal failure at mean 
age of 48 years. However, members without the associ­
ated PKDI haplotype did not enter ESRD before age of 
60 year. Haplotype analysis revealed the presence of a 
unique disease-associated haplotype in each family. In­
terfamily differences were detected when comparing 
overall survival. Family 1206 had the shortest survival, 
with a median age of 47.5 years, and family 1213 had the 
longest, with a median age of 77.4 years. For renal sur­
vival, the difference between families was highly signifi­
cant (P= 0.0001). 
PKD2 patients, compared with those who have 
PKDI, present with symptoms later in life, live 
longer, have a lower risk of progressing to renal fail­
ure, and have fewer complications (Table IV). In this 
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study, PKD2 was associated with a reduction of 17 
years in median survival to death or onset of ESRD 
compared wi t h  the survival o f  those w i t hout 
ADPKD. To o vercome this case-mix, as well as re­
gional differences, we defined the endpoint for over­
all survival as death or onset of ESRD. The current 
true survival f ig ures taking into account survival 
on dialysis will almost certainly be more optimistic, 
particularly for those with PKDl who have a higher 
risk of developing ESRD. Although the prevalence 
of hypertension in affected ADPKDl individuals 
increased with age (X2= 26.4, p<O.OOOOI), there was 
no significant difference between affected males and 
females (X2 = 0.14, p= 0.71). Against of this finding, 
males with ADPKD2 had significantly worse overall 
survival (p= 0 .0085), as well as renal survival (p= 
0.03) than females. 
DISCUSSION 
The diagnosis for presymptomatic ADPKD is mostly 
done by ultrasonography.24 The age dependent mani­
festation of ADPKD renders imaging techniques less 
effective diagnostic tools than genetic studies. PKD 1 is 
a big gene that generates a 14 kb transcript, and there 
are 3 regions highly homologous with the ex-globin genes 
at its 5' end.35 Mutations falling within the homologous 
regions are difficult to identify.54 
With the discovery of microsatellite markers closely 
associated with the PKDI and PKD2 gene loci, PCR 
amplification of these markers is increasingly being ap­
plied on presymptomatic and antenatal diagnosis.6,[6 In 
the present study, we used six markers for PKD 1 and 
PKD2 genes. Our survey of the allele frequencies of the 
microsatellites in the local population (Table II) provided 
data for a rational choice of markers in future ADPKD 
genetic linkage studies. KG8 and I 6AC2.5 had the high­
est heterozygosity rates and PIC values and were the 
most informative markers for the PKDl locus. SM7 had 
intermediate PIC values. PKD2 markers were not very 
informative individually, but were highly informative 
when used in combination. AFMl55xe ll had a low PIC 
value. The results of this study demonstrate significant 
locus heterogeneity in autosomal dominant PKD in Iran. 
The proportion of families linked in PKDl is estimated 
to be 78%. 
In our study, haplotypes were constructed in a num­
ber of ADPKD families using respective markers. As­
signment of the disease gene loci was performed follow­
ing phasing and haplotype construction, genotype/phe­
notype correlations were deduced from the constructed 
haplotypes. In studying the genotype/ phenotype cor­
relations we have focused on our patient's phenotype 
R. Radpour, et al. 
and found that high blood pressure is more prevalent in 
ADPKD patients than in non-affected relatives. 
Our study confirms the fact that PKD2 is a milder 
form of the disease. Although the age of ESRD seems not 
to be affected by prompt and effective treatment in order 
to avoid vascular complications. A clearer appreciation 
of the relative frequency of complications among people 
with PKDi and PKD2 has the potential to provide prac­
tical management guidance for those affected with 
ADPKD. Because of the technical demands and expense 
of both mutation detection and linkage analysis in 
ADPKD, identification of the genotype is not currently 
possible in the majority of cases. Nevertheless, the find­
ings of a higher prevalence of hypertension and the 
poorer cumulative overall survival probability in PKDi 
than in PKD2, support views that hypertension in ADPKD 
has a deleterious effect, particularly on renal survival, 
although the more rapid progression of P KD i-associ­
ated disease may be due to pathogenetic mechanisms 
unrelated to hypertension. Although our data have con­
firmed that PKD2 is clinically milder than PKDJ, the ad­
verse effect on survival shows that it cannot be regarded 
as a benign disorder. 
In the course of our study we encountered some limi­
tations of genetic linkage studies and some of the inves­
tigated families have no linkage to either of the known 
gene loci; the absence of clear linkage in these families 
does not necessarily imply the presence of another dis­
ease locus and the existence of a third locus for ADPKD 
remains uncertain at this study. 53 A number of potential 
confounders, including genotyping errors, no paternity, 
misdiagnosis, and bilineal disease, could lead to false 
exclusion of linkage and will need to be vigorously ex­
cluded in these families. But having more siblings within 
the families generally gives more information for haplo­
type construction and data interpretation. 59 With in­
creased emigration and a tendency to have smaller fami­
lies, it could be difficult to establish the haplotype of 
markers associated with the disease in some families. 
This problem is compounded in the study of ADPKD 
due to its genetic heterogeneity. 
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